U.S. Life Sciences Stock News

Sportradar Group entered this earnings season with a stock that had already been under pressure over the past month. The latest report then triggered a sharp 15% slide to €12.34, as the market focused on a fresh quarterly net loss and softer sentiment around growth bets in sports data and betting technology. Beneath that reaction, the headline was different. Sportradar Group reported €378m of Q2 revenue and solid adjusted earnings before interest, tax, depreciation and amortisation, supported...

Align Technology guidance update and what it could mean for investors Align Technology (ALGN) issued new earnings guidance for the third quarter and full year 2026 on July 29, alongside second quarter results and a buyback update, giving investors fresh data points to assess the stock. See our latest analysis for Align Technology. Guidance for softer third quarter revenue, one time restructuring charges and the recent product updates around Align Technology’s digital platform appear to be...

Global growth downgrades, sticky inflation and supply chain disruptions are pushing investors to reassess where risk and resilience really sit in their portfolios. At the same time, governments are increasing funding for renewable energy and green technologies, which can reshape expectations for future cash flows and policy support across the sector. This article looks at how that mix of pressure and support may affect selected renewable energy stocks today. It will walk through 3 stocks from...

Kosmos Energy came into this earnings print with a value label attached, trading on a low price to sales multiple and sitting at US$2.69 at the prior close. The stock then slipped nearly 6% to US$2.53 as the market digested the Q2 2026 release. That move was accompanied by a shift back into profit, with basic earnings per share of US$0.31 and net income of US$184.8m on US$607.6m of revenue. For a company known for persistent losses and balance sheet worries, this quarter places profitability...

First Horizon stock has more than doubled over the past three years, yet the latest intrinsic value work using the Excess Returns model suggests the market price may still be below what the underlying business justifies. First Horizon has returned 108.5% over the past three years, which puts extra focus on whether recent gains already reflect its fundamentals. The company run stress test results, which show capital ratios staying well above regulatory minimums in severe scenarios, can...

Big tech gains lifting the Nasdaq and S&P 500, easing oil prices after US Iran diplomatic moves, and fresh signals of manufacturing strength have put US Consumer Discretionary stocks back in focus. With investors watching earnings from high profile names like Palantir and SpaceX and looking ahead to the next jobs report, some larger US consumer focused companies in our screener look closely tied to these trends. This article breaks down 3 stocks that appear positively exposed to the latest...

Graham Holdings Company reported past second-quarter and first-half 2026 results, with revenue rising to US$1,302.51 million and US$2,538.50 million, and net income increasing to US$281.10 million and US$310.21 million, respectively, alongside much higher earnings per share from continuing operations versus a year earlier. The jump in earnings per share from continuing operations, from US$8.35 diluted a year ago to US$64.86, highlights a very large improvement in profitability across the...

Indivior Pharmaceuticals stock just shed 6.6% in a single session, yet the latest quarter reads more like a profitability step change than a collapse in confidence. The company printed Q2 basic earnings per share of US$1.02 on revenue of US$343 million, both comfortably above the prior quarter levels. Over the trailing twelve months that has translated into a 26.7% net margin against just 9.2% a year earlier. The market is focusing on the headline price drop. The earnings story is about a...

Rising inflation, hawkish comments from Federal Reserve officials and uncertainty around the next move on interest rates are reshaping how investors think about banks and insurers. Some stocks could benefit if higher rates support lending margins or investment income, while others may face pressure from funding costs and credit risks. This article focuses on three stocks from our Financial Sector screener that appear closely tied to these rate and policy trends. You will see how each stock is...

AES stock is back in focus as a potential takeover and a long term share price decline of 26.1% over five years meet a set of valuation checks that currently lean cheap, including an intrinsic value estimate from a Discounted Cash Flow (DCF) that points to meaningful upside versus the market price. Over the past five years, AES shares have declined 26.1%, which keeps the stock trading well below where longer term holders bought in and puts more weight on whether today’s price offers a margin...

FedEx stock has returned 76.0% over the past year, yet both its Discounted Cash Flow (DCF) intrinsic value estimate and earnings multiples currently lean toward the shares trading below what the fundamentals imply. That sets up an important check for investors on whether the recent gains have simply closed a gap or if the market is still pricing FedEx cautiously. FedEx has gained 76.0% over the past year, which puts the current share price in sharp focus against its underlying earnings power...

In July 2026, AtriCure, Inc. reported second-quarter results showing higher revenue of US$153.6 million and a shift from a net loss to net income of US$8.96 million, alongside new full-year 2026 guidance projecting revenue of US$602 million to US$610 million and net income per share of US$0.05 to US$0.13. On the same day, AtriCure also filed two ESOP-related shelf registrations for up to 2,250,000 common shares totaling US$78.84 million, highlighting both improving profitability and plans to...

The market just marked TG Therapeutics down hard, with the stock dropping about 11% the day after earnings, even as the core multiple sclerosis drug story looked stronger on the surface. Investors came in after a solid 12 month run, only to be met with an earnings print that paired powerful BRIUMVI revenue of about US$228 million with a sharp hit to bottom line profit. The headline this quarter is margin pressure. Heavy manufacturing related charges cut reported net income to US$7.8 million...

Ocular Therapeutix stock inched up about 3% to US$8.40 after earnings, a modest move for a biotech that has been drifting lower over the past quarter. The headline is not about a sudden swing into profit. It is about how much revenue growth investors are willing to pay for when the losses remain heavy. Quarterly revenue sat in the low teens in millions of US dollars, while net loss stayed deep in the tens of millions. That mix keeps the spotlight on the long term. For anyone looking at Ocular...

Lantheus Holdings stock has delivered very strong returns over the past few years, yet the current price sits close to the agreed cash offer from Curium, which raises questions about how much upside is left in the valuation. Over the past 5 years, Lantheus Holdings has returned about 294.0%, which puts recent share price moves into the context of a very strong multi year run. The agreed Curium acquisition, with a headline value of up to US$8b tied to milestones, can anchor expectations for...

Compugen stock barely flinched after earnings, ticking up about 1% to US$2.38, yet the real story sits far beyond today’s modest move. You are looking at a biotech that has just posted another small quarter of revenue at US$2.6m and a quarterly net loss of about US$7m, while still carrying a price tag of only 6.4x trailing earnings. The time horizon is the tension. In the short term, Q2 is about controlled burn and a long cash runway into 2029. Over multiple years, the debate shifts to...

Ryerson Holding Corporation recently reported past second-quarter 2026 results, with sales of US$2.01 billion and net income of US$15.5 million, while also declaring a quarterly cash dividend of US$0.1875 per share payable on September 17, 2026. Alongside this, the company issued third-quarter guidance targeting net income of US$19 million to US$21 million and net sales of US$1.87 billion to US$1.95 billion, offering investors a clearer view of its near-term earnings outlook. With this new...

Lindblad Expeditions Holdings stock jumped almost 12% to $33.12 after the Q2 print, capping a strong run over the past three months. The move reflects how quickly investors rewarded a clearer story around profitability. Q2 revenue came in at about $199.2 million, with adjusted earnings before interest, tax, depreciation and amortization margin at 16.3%, and occupancy at 91% on its expedition sailings. The excitement sits against a tougher backdrop. Lindblad remains loss making on a trailing...

Sally Beauty Holdings walked into this report priced as a discounted, debt‑laden specialty retailer. The stock had already climbed over the past month, and the real jolt came today with a 7.8% jump to US$16.13 after earnings hit the tape. The headline is simple: profit quality surprised in a business many investors still treat as ex growth. Adjusted earnings per share landed around the mid US$0.50s and trailing twelve month earnings reached just under US$2 per share, while net profit margin...

ExxonMobil Holdings (NYSE:XOM) executives warn that global refining bottlenecks, worsened by conflicts involving Russia and in the Middle East, could keep fuel prices elevated even if crude oil prices soften. Chevron issues similar caution on refining capacity, reinforcing concerns about a prolonged period of higher fuel costs for end consumers. Former President Donald Trump publicly criticizes ExxonMobil for what he describes as excessive wartime profits linked to the current conflict with...

Atkore entered this quarter with a reputation as a solid electrical infrastructure supplier but was dealing with fresh losses. The stock had already been on a strong run, yet the market’s reaction to Q3 was explosive. Shares jumped about 28% to roughly US$93.55 in regular trading after the release. The headline is not spectacular profit growth; it is that revenue reached about US$794.8m and earnings swung from a heavy recent loss to a small profit of roughly US$0.7m. For a company still...

Bowhead Specialty Holdings just rose 10.1% in a single session, and the mood looks more euphoric than confused. The stock came into the print already riding a strong 90 day run, yet traders still paid up after seeing another solid quarter of underwriting and earnings delivery. Quarterly basic earnings per share of US$0.48, together with revenue of US$163.9m, gave investors enough confidence to lean into the move, even with the trailing P/E already sitting at 17.9x. Impressed by Bowhead...

Easterly Government Properties stock closed up 3.8% today, yet the real story sits inside a quiet but important improvement in its cash engine. For a real estate investment trust, funds from operations matter more than headline earnings, and Q2 delivered US$37.3m of funds from operations alongside US$94.0m of revenue. That combination helped management lift full year core funds from operations per share guidance, a small move on paper that carries outsized weight for investors who focus on...

Interest rate stories rarely stay contained to bond traders. The recent US Japan currency intervention and expanded use of the Fed’s FIMA repo facility have direct implications for US financials and interest rate sensitive sectors, from lenders to real estate and housing related companies. Shifts in Treasury yield pressures and currency flows can change funding costs, balance sheet values and investor appetite. This article walks through 3 US listed stocks from our Financials and Interest...